REZOHIN table. 250 mg. 100 table

REZOHIN table. 250 mg. 100 table
€ 41.00
Add to Cart
Prevention and treatment of malaria caused by four types of malaria pathogens that are pathogenic to humans, except that caused by chloroquine-resistant strains. Extraintestinal amebiasis (kind of parasitic disease) when nitroimidazolovite products are ineffective or can not be used

REZOHIN table. 250 mg. 100 table
 

Active ingredient: chloroquine (chloroquine) Tablets

Staff
 
1 tablet contains 250 mg of chloroquine phosphate (chloroquine phosphate), corresponding to 155 mg chloroquine {chloroquine).
 
Help ingredients: corn starch, talc, magnesium stearate, hypromellose, macrogol 4000, titanium (IV) oxide (171).
 
Witness
 
Prevention and treatment of malaria caused by four types of malaria pathogens that are pathogenic to humans, except that caused by chloroquine-resistant strains.
 
Extraintestinal amebiasis (kind of parasitic disease) when nitroimidazolovite products are ineffective or can not be used.
 
Chronic arthritis (RA), including rheumatoid arthritis in children (juvenile).
 
Systemic lupus erythematosus.
 
Contraindication
Resochin should not be used in patients with known hypersensitivity to 4-aminohinoloni, patients with retinal damage (retinopathy) or visual field damage, abnormal blood formation, patients with a deficiency of the enzyme glucose-6-phosphate dehydrogenase (favizam; symptom: hemolytic anemia), a neurological disorder myasthenia gravis, pregnant or lactating women (exceptions: treatment and prevention of malaria) (see use during pregnancy or lactation).
 

Use in pregnancy


 

Data on adverse events after use of the drug during the first three months of pregnancy are very limited. Therefore, the drug should be used during pregnancy only if absolutely indicated. The risk / benefit should be considered when advising pregnant women, because the risks of malaria during pregnancy may outweigh harmful effects of chemotherapy. Chloroquine crosses the placenta and can cause damage to the organs of the fetus.
 
Therefore, chloroquine is contraindicated during pregnancy (except malaria). If risk of illness from malaria, after consideration of the benefit / risk decision should generally be in favor of using chloroquine as malaria infection itself damaging the fetus.
 
Before beginning treatment with chloroquine should exclude the possibility of pregnancy (except malaria) during treatment to ensure effective contraception, which should continue for at least three months after treatment.
 
For prevention of malaria with chloroquine with the proposed dosage is recommended contraception for the duration of prophylaxis and three months afterwards.
 
Use during lactation
2-4% of the dose chloroquine passes into breast milk. Although no known cases where infants were harmed by breast milk containing chloroquine as a precautionary measure, breast-feeding should be discontinued during treatment with this medication.
 
Effects on ability to drive and use machines
 
Taking into account the side effects of chloroquine on the central nervous system (headache, dizziness, somnolence) ability to drive and use machines may be impaired due to accommodation disorders and visual Scotoma. This is particularly true for the beginning of treatment and periodically during treatment in combination with alcohol and sedatives.
  
Special precautions for use
 
To verify the existence of possible adverse visual effects to make eye examination before treatment and continued to be repeated at 3-month intervals during the course of treatment. The first symptom of retinopathy (loss of ability to perceive the color red), treatment should be discontinued.
Blood counts should be checked before treatment and continued thereafter bimonthly intervals. 
Epileptics treated with chloroquine need regular medical examinations.
Patients with impaired hepatic or renal function may further require dose adjustment.
Patients women who take chloroquine for long-term prevention of malaria should be sure to use adequate contraception during this time and should not become pregnant three months after discontinuation of prophylactic treatment.
 
Resochin should not be used in patients with psoriasis or porphyria (a metabolic abnormality). Resochin should not be used in children for long-term prevention of malariya.Ne recommended the use of chloroquine in patients with renal insufficiency with creatinine clearance below 10 ml / min due to lack of data.
 
Adverse Reactions
 
The majority of side effects observed after administration of chloroquine dose-dependent and occurred mainly at plasma concentrations above 250 mcg / l.
 
The incidence of chloroquine-induced retinopathy depend daily dose. If the daily dose (2,5 mg chloroquine base / kg during continuation therapy in patients with normal renal function) are strictly followed, damage to the retina are rare.
 
 Interaction with other medicinal products and other forms of interaction
 
Antacids and kaolin can reduce absorption of chloroquine and are advised to take at least four hours after chloroquine. Reported that chloroquine reduces immune response to human diploid cell rabies vaccine, there was no impairment of the immune response to other vaccines used in routine immunization (tetanus, diphtheria, measles, polio, typhoid, and BCG). Center for Control and Prevention of Disease (Department of Health and Human Services, US) is currently recommended for the prevention of rabies HCDV be administered intramuscularly, intradermally not, as it can get sufficient protection against rabies after intradermal administration of the vaccine, while intramuscular application is suitable for providing adequate performance in these subjects.
 
Co-administration of phenylbutazone increased likelihood of developing dermatitis (exfoliative). Probenecid increases the risk of sensitization.
 
Concomitant use of corticosteroid derivatives can exacerbate existing conditions and heart muscle (myopathies and cardiomyopathies).
 
Chloroquine is recommended not with molecules with a degree of damage to the liver, (such as isoniazid, amiodarone, carbamazepine, phenytoin, fenotiazidi and ketoconazole) or MAO inhibitors (eg phenelzine, traniltsipromid, isocarboxazid, and selegiline). Continuous co-administration with digoxin may cause intoxication glucosides by increased plasma digoxin concentrations.
 
The effect of folic acid antagonists (methotrexate) is potentiated by hlorokvin.Hlorokvin is an antagonist of the action of neostigmine and pyridostigmine. Concurrent use with cyclosporine may cause a sudden increase in plasma concentrations of cyclosporine. Chloroquine may also reduce gastrointestinal. absorption of ampicillin, so ampicillin is recommended to be taken at least 2 hours after chloroquine.
 
Cimetidine may reduce the excretion of chloroquine.
 
The concomitant use of mefloquine and buproprion may increase the risk of pripadatsi.Ostra dystonic reaction was observed after co-administration of chloroquine and metronidazole.
 
Concomitant use with penicillamine may increase the potential for serious hematologic and / or renal adverse effects associated with penicillamine and skin reaktsii.Kombinatsiyata of chloroquine and pyrimethamine / sulfadoksin significantly increases the risk of skin reactions.
 
Co-acceptance of chloroquine and pratsikvantel can lead to lower levels of blood pratsikvantel.
 
 Dosage
 
1. Prevention of malaria
 
The generally recommended dosage is as follows: after an initial oral dose of 2x5 mg chloroquine base / kg body weight, the usual maintenance dose is 5 mg chloroquine base / kg body weight once a week.
 Adults:
 
When prophylaxis with chloroquine should begin 1 to 2 weeks before entering the malaria zone is recommended that adults receive oral starting dose of 1 g chloroquine diphosphate (4 tablets of chloroquine), divided into two equal doses (2x2) for 6 hours. If prevention starts at the beginning of the trip should take 2 tablets (500 mg chloroquine) in the coming days, followed by regular maintenance dosage of 2 tablets of chloroquine once a week, taken on the same day each week, an additional 4-6 weeks after leaving the malarial area.
 
Children:
 
Unless prescribed otherwise, children receive oral doses in proportion to their body weight.
 
Usage
Tablets should always be taken on the same day each week and should be swallowed whole with a little water after meals.
 
Duration of use
 
Prophylactic treatment should be continued with. same dose for additional 4-6 weeks after leaving the malarial area.
 
The total adult dose should not exceed 100 g chloroquine base in line with WHO recommendations. At a dose of 2 tablets Resochin week, it should not be taken for more than six years. Then prophylaxis should be continued with a substance that contains chloroquine (the active ingredient in Resochin). Resochin should not be used for long term prophylaxis of malaria in children.
 

 Treatment of Malaria

 
Unless prescribed otherwise, the total dose in the treatment of malaria caused by chloroquine-sensitive parasites is 25-30 mg chloroquine base / kg body weight. This dose should be administered orally, divided over 3-4 days: early chloroquine base 10 mg / kg body weight six hours later, 5 mg chloroquine base / kg and another 5 mg / kg, daily for the next 2-3 days.
 
Adults:
 
Adults get in the top 4 tablets Resochin, 6 hours later, 2 tablets Resochin, then 2 tablets daily for Resochin 2-3 days.
 
Children:
 
Children receive oral dose equivalent to their body weight.
 
Usage
 
Tablets should always be taken on the same day each week and should be swallowed whole with a little water after meals.
 
LechenietoRezultatite Duration of treatment can be assessed soon after 4-12 weeks. If there is no improvement after six months, treatment should be discontinued. In line with WHO recommendations, the total cumulative dose should not exceed 100 g chloroquine base. With prolonged treatment of rheumatism with a dose of 1 tablet per day Resochin, this corresponds to a period of about two years.
 
 

 Chronic arthritis (RA), systemic lupus erythematosus


 


Adults:

 
Due to the risk of retinopathy, developing after prolonged use, the daily dose should not exceed 2,5 mg chloroquine base, corresponding to a dose of 1 tablet per day Resochin.
 

Children:

 
The daily dose for children is also 2,5 mg chloroquine base / kg. If there is no improvement after six months, treatment should be discontinued.
  
Usage
 
Tablets should always be taken on the same day each week and should be swallowed whole with a little water after meals.
 

  Ekstraintestinalna amebiasis

 
 Unless prescribed otherwise, adults standard dose chloroquine for treatment of amebiasis ekstraintestinalnata applied only in combination with other active substances is 600 mg chloroquine base / day for two days followed by 300 mg base / day for 14 - 28 dni.Po thus get older Resochin 4 tablets daily for two days, followed by 2 tablets Resochin daily for 14-28 days.
 
Children receive a base of 10 mg / day as a daily dose for two days, followed by 5 mg base / kg, daily for 14 to 28 days.
 
Usage
 
Tablets should always be taken on the same day each week and should be swallowed whole with a little water after meals.
 

Overdose in children

 
In cases where a child is adopted Resochin tablets without control at the moment, you should contact your doctor and immediately induce vomiting. Recommended following procedures: Infants: Ask the child to drink as much fruit juice diluted with water, then place it on the knee of an adult (head and face are down) so that the abdomen is slightly compressed. Induce vomiting by irritating the back of the throat (pharynx) with your finger or the handle of a spoon.
 
Have the child drink warm salt water (1 teaspoon salt to a glass of water), then induce vomiting by irritating the back of the pharynx with the finger or the handle of a spoon. Child to continue to drink salt water until they vomit clear liquid.
 
Expiration date
 
60 months.
 
Rezohin should not be used after the expiry date.
 Special precautions for storage
Do not store above 30 ° C. Keep out of reach of children.
 
€ 41.00
Add to Cart
Close